为解决腺相关病毒（AAV）载体中未甲基化的 CpG 二核苷酸引发免疫反应影响治疗效果的问题，研究人员开展优化富含 CpG 的 AAV8 载体 pVR59 的研究。结果得到 CpG 缺失载体 pNC182，维持疗效且降低免疫反应，为 LPLD 治疗及 AAV 载体设计提供思路。 腺相关病毒（Adeno ...

卵巢癌死亡率高，免疫检查点抑制剂治疗效果不佳且副作用大。研究人员利用腺相关病毒 - 成簇规律间隔短回文重复序列 / Cas9 ...

CDMO 3PBIOVIAN officials report that the company has launched the AAVion ® platform, a fully integrated adeno-associated virus (AAV) manufacturing solution designed to accelerate gene therapy ...

Paulk, PhD, Siren Biotechnology’s CEO and Founder. “These presentations reflect our continued progress advancing our Universal AAV Immuno-Gene Therapy Platform and our commitment to developing ...

Gene therapy represents one of the fastest growing biotherapeutics worldwide, with AAV at the forefront. This rapid growth is constantly challenging CMC approaches, from manufacturing through release ...

--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV ...